{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"ATNM","limit":50},"count":50,"signals":[{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":70,"context":"as necessary to respond to developments in our business and other factors, and any such modification such as a divestiture, spin-off, spin-out, merger or acquisition, if not successful, could have a material adverse effect on our business, financial condition, and results of operations; | | |  |  |  We may expand our business through the acquisition of rights to new product candidates that could disrupt our business, h","filed_date":"2026-03-30","accession":"0001213900-26-036504","full_text":"https://origin.rootz.global/static/filing/0001213900-26-036504.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":46,"context":"as necessary to respond to developments in our business and other factors, and any such modification such as a divestiture, spin-off, spin-out, merger or acquisition, if not successful, could have a material adverse effect on our business, financial condition, and results of operations. 2 Phase 2/3 Trials and 4 Phase 1 Trials Supported by NCI CRADA * **Key Value Drivers** |  - | Clinical Validation: Data in over 500 pa","filed_date":"2025-11-14","accession":"0001213900-25-110979","full_text":"https://origin.rootz.global/static/filing/0001213900-25-110979.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":35,"context":"appointment of CBIZ CPAs P.C. as our independent registered public accounting firm for the fiscal year ending December31, 2025; 3.To approve, on a non-binding advisory basis, the compensation of our named executive officers; and 4. To approve, on a non-binding advisory basis, the frequency of holding future advisory votes on the compensation of our named executive officers. In addition, stockholders may be asked to con","filed_date":"2025-11-05","accession":"0001213900-25-106706","full_text":"https://origin.rootz.global/static/filing/0001213900-25-106706.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":46,"context":"as necessary to respond to developments in our business and other factors, and any such modification such as a divestiture, spin-off, spin-out, merger or acquisition, if not successful, could have a material adverse effect on our business, financial condition, and results of operations; | | |  |  |  | | |  |  |  We may expand our business through the acquisition of rights to new product candidates that could disrupt ou","filed_date":"2025-08-08","accession":"0001213900-25-073743","full_text":"https://origin.rootz.global/static/filing/0001213900-25-073743.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":46,"context":"uously evaluate our business strategy and may modify our strategy as necessary to respond to developments in our business and other factors, and any such modification, if not successful, could have a material adverse effect on our business, financial condition, and results of operations; | | |  |  |  | | |  |  |  Our business could be adversely affected by the effects of future health epidemics; | | |  |  |  | | |  |  |","filed_date":"2025-05-09","accession":"0001213900-25-041614","full_text":"https://origin.rootz.global/static/filing/0001213900-25-041614.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":64,"context":"uously evaluate our business strategy and may modify our strategy as necessary to respond to developments in our business and other factors, and any such modification, if not successful, could have a material adverse effect on our business, financial condition, and results of operations; | | |  |  |  | | |  |  |  Our business could be adversely affected by the effects of future health epidemics; | | |  |  |  | | |  |  |","filed_date":"2025-03-31","accession":"0001213900-25-026371","full_text":"https://origin.rootz.global/static/filing/0001213900-25-026371.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":35,"context":"uously evaluate our business strategy and may modify our strategy as necessary to respond to developments in our business and other factors, and any such modification, if not successful, could have a material adverse effect on our business, financial condition, and results of operations; | | |  |  |  | | |  |  |  Our business could be adversely affected by the effects of future health epidemics; | | |  |  |  | | |  |  |","filed_date":"2024-11-14","accession":"0001213900-24-098534","full_text":"https://origin.rootz.global/static/filing/0001213900-24-098534.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":32,"context":"reform measures intended to increase pressure to reduce prices of pharmaceutical products paid for by Medicare or, otherwise, affect the federal regulation of the U.S. healthcare system could have a material adverse effect our business, future revenue, if any, and results of operations; | | |  |  |  We may rely on third parties to conduct certain aspects of our clinical trials. If these third parties do not successfull","filed_date":"2024-08-05","accession":"0001213900-24-065239","full_text":"https://origin.rootz.global/static/filing/0001213900-24-065239.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":33,"context":"reform measures intended to increase pressure to reduce prices of pharmaceutical products paid for by Medicare or, otherwise, affect the federal regulation of the U.S. healthcare system could have a material adverse effect our business, future revenue, if any, and results of operations; | | |  |  |  We may rely on third parties to conduct certain aspects of our clinical trials. If these third parties do not successfull","filed_date":"2024-04-26","accession":"0001213900-24-036699","full_text":"https://origin.rootz.global/static/filing/0001213900-24-036699.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":60,"context":"reform measures intended to increase pressure to reduce prices of pharmaceutical products paid for by Medicare or, otherwise, affect the federal regulation of the U.S. healthcare system could have a material adverse effect our business, future revenue, if any, and results of operations; | | |  |  |  We may rely on third parties to conduct certain aspects of our clinical trials. If these third parties do not successfull","filed_date":"2024-03-29","accession":"0001213900-24-028038","full_text":"https://origin.rootz.global/static/filing/0001213900-24-028038.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":32,"context":"reform measures intended to increase pressure to reduce prices of pharmaceutical products paid for by Medicare or, otherwise, affect the federal regulation of the U.S. healthcare system could have a material adverse effect our business, future revenue, if any, and results of operations; | | 41 |  |  |  We rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their co","filed_date":"2023-11-02","accession":"0001213900-23-082459","full_text":"https://origin.rootz.global/static/filing/0001213900-23-082459.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":32,"context":"reform measures intended to increase pressure to reduce prices of pharmaceutical products paid for by Medicare or, otherwise, affect the federal regulation of the U.S. healthcare system could have a material adverse effect our business, future revenue, if any, and results of operations; | | 42 |  |  |  We rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their co","filed_date":"2023-08-14","accession":"0001213900-23-067199","full_text":"https://origin.rootz.global/static/filing/0001213900-23-067199.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":32,"context":"reform measures intended to increase pressure to reduce prices of pharmaceutical products paid for by Medicare or, otherwise, affect the federal regulation of the U.S. healthcare system could have a material adverse effect our business, future revenue, if any, and results of operations; | | 40 |  |  |  We rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their co","filed_date":"2023-05-15","accession":"0001213900-23-039902","full_text":"https://origin.rootz.global/static/filing/0001213900-23-039902.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":33,"context":"reform measures intended to increase pressure to reduce prices of pharmaceutical products paid for by Medicare or, otherwise, affect the federal regulation of the U.S. healthcare system could have a material adverse effect our business, future revenue, if any, and results of operations; | | |  |  |  | | |  |  |  We rely on third parties to conduct our clinical trials. If these third parties do not successfully carry ou","filed_date":"2023-03-31","accession":"0001213900-23-025597","full_text":"https://origin.rootz.global/static/filing/0001213900-23-025597.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":25,"context":"across the healthcare and life sciences industries &#x2022;&#x00a0;&#x00a0;&#x00a0;Led Corporate Strategy at Immunomedics to help transform the clinical-stage company into a commercial organization (acquired by Gilead for $21BN following the FDA approval of Trodelvy&#x00ae; in triple-negative breast cancer) &#x2022;&#x00a0;&#x00a0;&#x00a0;Advised payers, providers, and life sciences companies as a management consultant","filed_date":"2022-11-21","accession":"0001213900-22-074269","full_text":"https://origin.rootz.global/static/filing/0001213900-22-074269.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":33,"context":"ns. Therefore, the COVID-19 pandemic, may further divert the attention and efforts of the medical community to coping with COVID-19, and may disrupt the marketplace in which we operate and may have a material adverse effect on our operations. 22 A continuation or worsening of the levels of market disruption and volatility seen in the recent past could have an adverse effect on our ability to access capital, which could","filed_date":"2022-11-14","accession":"0001213900-22-072371","full_text":"https://origin.rootz.global/static/filing/0001213900-22-072371.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"velopment strategy is actively informed by clinical data with Iomab-B and Actimab-A in approximately 600 patients, including our ongoing Pivotal Phase 3 SIERRA trial, which completed its targeted enrollment of 150 patients in the third quarter of 2021, with the last patient receiving their BMT in the fourth quarter of 2021. Our clinical pipeline has emanated from our Antibody Warhead Enabling (AWE) t","filed_date":"2022-08-12","accession":"0001213900-22-047496","full_text":"https://origin.rootz.global/static/filing/0001213900-22-047496.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":33,"context":"emic may continue to affect our operation, may further divert the attention and efforts of the medical community to coping with COVID-19 and disrupt the marketplace in which we operate and may have a material adverse effect on our operations. 21 A continuation or worsening of the levels of market disruption and volatility seen in the recent past could have an adverse effect on our ability to access capital, which could","filed_date":"2022-08-12","accession":"0001213900-22-047496","full_text":"https://origin.rootz.global/static/filing/0001213900-22-047496.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":40,"context":"d in the Registration Statement and the Prospectus, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect or would reasonably be expected to have a material adverse effect on or affecting the assets, business, operations, earnings, properties, financial condition, prospects, stockholders equity or result","filed_date":"2022-06-29","accession":"0001213900-22-035693","full_text":"https://origin.rootz.global/static/filing/0001213900-22-035693.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":17,"context":"velopment strategy is actively informed by clinical data with Iomab-B and Actimab-A in approximately 600 patients, including our ongoing Pivotal Phase 3 SIERRA trial, which completed its targeted enrollment of 150 patients in the third quarter of 2021, with the last patient receiving their BMT in the fourth quarter of 2021. Our clinical pipeline has emanated from our Antibody Warhead Enabling (AWE) t","filed_date":"2022-05-13","accession":"0001213900-22-026538","full_text":"https://origin.rootz.global/static/filing/0001213900-22-026538.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":33,"context":"emic may continue to affect our operation, may further divert the attention and efforts of the medical community to coping with COVID-19 and disrupt the marketplace in which we operate and may have a material adverse effect on our operations. A continuation or worsening of the levels of market disruption and volatility seen in the recent past could have an adverse effect on our ability to access capital, which could in","filed_date":"2022-05-13","accession":"0001213900-22-026538","full_text":"https://origin.rootz.global/static/filing/0001213900-22-026538.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":19,"context":"velopment strategy is actively informed by clinical data with Iomab-B and Actimab-A in approximately 600 patients, including our ongoing Pivotal Phase 3 SIERRA trial, which completed its targeted enrollment of 150 patients in the third quarter of 2021, with the last patient receiving their BMT in the fourth quarter of 2021. Our clinical pipeline has emanated from our Antibody Warhead Enabling (AWE) t","filed_date":"2022-03-25","accession":"0001213900-22-015208","full_text":"https://origin.rootz.global/static/filing/0001213900-22-015208.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":35,"context":"emic may continue to affect our operation, may further divert the attention and efforts of the medical community to coping with COVID-19 and disrupt the marketplace in which we operate and may have a material adverse effect on our operations. A continuation or worsening of the levels of market disruption and volatility seen in the recent past could have an adverse effect on our ability to access capital, which could in","filed_date":"2022-03-25","accession":"0001213900-22-015208","full_text":"https://origin.rootz.global/static/filing/0001213900-22-015208.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":20,"context":"lopment strategy is actively informed by clinical data with its ARCs in approximately 600 patients, including the pivotal Phase 3 SIERRA trial for the Companys lead asset Iomab-B, which completed enrollment of 150 patients in September 2021. The clinical pipeline has emanated from its Antibody Warhead Enabling (AWE) technology platform, which is protected by over 160 issued patents and pending patent","filed_date":"2021-11-12","accession":"0001213900-21-058783","full_text":"https://origin.rootz.global/static/filing/0001213900-21-058783.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":32,"context":"emic may continue to affect our operation, may further divert the attention and efforts of the medical community to coping with COVID-19 and disrupt the marketplace in which we operate and may have a material adverse effect on our operations. A continuation or worsening of the levels of market disruption and volatility seen in the recent past could have an adverse effect on our ability to access capital, which could in","filed_date":"2021-11-12","accession":"0001213900-21-058783","full_text":"https://origin.rootz.global/static/filing/0001213900-21-058783.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":20,"context":"rimary endpoint of the study. The SIERRA trial is currently active at 24 sites in the United States and Canada, which includes many of the leading BMT sites based on volume. We expect to complete enrollment of the SIERRA trial and have topline data that we believe will support the submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA). If approved, we exp","filed_date":"2021-07-30","accession":"0001213900-21-039595","full_text":"https://origin.rootz.global/static/filing/0001213900-21-039595.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":32,"context":"emic may continue to affect our operation, may further divert the attention and efforts of the medical community to coping with COVID-19 and disrupt the marketplace in which we operate and may have a material adverse effect on our operations. 20 A continuation or worsening of the levels of market disruption and volatility seen in the recent past could have an adverse effect on our ability to access capital, which could","filed_date":"2021-07-30","accession":"0001213900-21-039595","full_text":"https://origin.rootz.global/static/filing/0001213900-21-039595.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":21,"context":"rimary endpoint of the study. The SIERRA trial is currently active at 24 sites in the United States and Canada, which includes many of the leading BMT sites based on volume. We expect to complete enrollment of the SIERRA trial and have topline data that we believe will support the submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA). If approved, we exp","filed_date":"2021-05-14","accession":"0001213900-21-026493","full_text":"https://origin.rootz.global/static/filing/0001213900-21-026493.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":32,"context":"emic may continue to affect our operation, may further divert the attention and efforts of the medical community to coping with COVID-19 and disrupt the marketplace in which we operate and may have a material adverse effect on our operations. The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the ultimate economic impact brought by, and the duration of, the COV","filed_date":"2021-05-14","accession":"0001213900-21-026493","full_text":"https://origin.rootz.global/static/filing/0001213900-21-026493.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":19,"context":"primary endpoint of the study. The SIERRA trial is currently active at 5 sites in the United States and Canada, which includes many of the leading BMT sites based on volume. We expect to complete enrollment of the SIERRA trial and have topline data that we believe will support the submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA). If approved, we exp","filed_date":"2021-03-31","accession":"0001213900-21-019297","full_text":"https://origin.rootz.global/static/filing/0001213900-21-019297.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":33,"context":"reform measures intended to increase pressure to reduce prices of pharmaceutical products paid for by Medicare or, otherwise, affect the federal regulation of the U.S. healthcare system could have a material adverse effect our business, future revenue, if any, and results of operations; | | |  | | | | |  | | We rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out th","filed_date":"2021-03-31","accession":"0001213900-21-019297","full_text":"https://origin.rootz.global/static/filing/0001213900-21-019297.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"rimary endpoint of the study. The SIERRA trial is currently active at 20 sites in the United States and Canada, which includes many of the leading BMT sites based on volume. We expect to complete enrollment of the SIERRA trial and have topline data that we believe will support the submission of a Biologics License Application, or BLA, with the U.S. Food and Drug Administration, or FDA, in 2021. If ap","filed_date":"2020-10-23","accession":"0001213900-20-033053","full_text":"https://origin.rootz.global/static/filing/0001213900-20-033053.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":30,"context":"emic may continue to affect our operation, may further divert the attention and efforts of the medical community to coping with COVID-19 and disrupt the marketplace in which we operate and may have a material adverse effect on our operations. The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the ultimate economic impact brought by, and the duration of, the COV","filed_date":"2020-10-23","accession":"0001213900-20-033053","full_text":"https://origin.rootz.global/static/filing/0001213900-20-033053.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"rimary endpoint of the study. The SIERRA trial is currently active at 20 sites in the United States and Canada, which includes many of the leading BMT sites based on volume. We expect to complete enrollment of the SIERRA trial and have topline data that we believe will support the submission of a Biologics License Application, or BLA, with the U.S. Food and Drug Administration, or FDA, in 2021. If ap","filed_date":"2020-08-14","accession":"0001213900-20-022334","full_text":"https://origin.rootz.global/static/filing/0001213900-20-022334.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":30,"context":"emic may continue to affect our operation, may further divert the attention and efforts of the medical community to coping with COVID-19 and disrupt the marketplace in which we operate and may have a material adverse effect on our operations. 19 The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the ultimate economic impact brought by, and the duration of, the","filed_date":"2020-08-14","accession":"0001213900-20-022334","full_text":"https://origin.rootz.global/static/filing/0001213900-20-022334.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"rimary endpoint of the study. The SIERRA trial is currently active at 20 sites in the United States and Canada, which includes many of the leading BMT sites based on volume. We expect to complete enrollment of the SIERRA trial and have topline data that we believe will support the submission of a Biologics License Application, or BLA, with the U.S. Food and Drug Administration, or FDA, in 2021. If ap","filed_date":"2020-06-29","accession":"0001213900-20-016168","full_text":"https://origin.rootz.global/static/filing/0001213900-20-016168.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":28,"context":"Iomab-B receives favorable regulatory approval, we may not be successful in securing adequate reimbursement or establishing successful commercial operations. Any or all of these factors could have a material adverse impact on our business and ability to continue operations. 28 **We may be unable to establish sales, marketing and commercial supply capabilities** We do not currently have, nor have we ever had, commercial","filed_date":"2020-06-29","accession":"0001213900-20-016168","full_text":"https://origin.rootz.global/static/filing/0001213900-20-016168.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"rimary endpoint of the study. The SIERRA trial is currently active at 20 sites in the United States and Canada, which includes many of the leading BMT sites based on volume. We expect to complete enrollment of the SIERRA trial and have topline data that we believe will support the submission of a Biologics License Application, or BLA, with the U.S. Food and Drug Administration, or FDA, in 2021. If ap","filed_date":"2020-05-08","accession":"0001213900-20-011475","full_text":"https://origin.rootz.global/static/filing/0001213900-20-011475.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"Iomab-B receives favorable regulatory approval, we may not be successful in securing adequate reimbursement or establishing successful commercial operations. Any or all of these factors could have a material adverse impact on our business and ability to continue operations. **We may be unable to establish sales, marketing and commercial supply capabilities** We do not currently have, nor have we ever had, commercial sa","filed_date":"2020-05-08","accession":"0001213900-20-011475","full_text":"https://origin.rootz.global/static/filing/0001213900-20-011475.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":42,"context":"number of shares of common stock, par value $0.001 per share, the corporation is authorized to issue by 400,000,000; and |  | |  | 6. | To hold a non-binding advisory vote on the compensation of our named executive officers; and. |  | |  | 7. | To hold a non-binding advisory vote to determine the frequency of future advisory votes on the compensation of the named executive officers. |  | In addition, stockholders may b","filed_date":"2019-11-25","accession":"0001213900-19-024628","full_text":"https://origin.rootz.global/static/filing/0001213900-19-024628.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":14,"context":"ations longer-term. If the Company is unsuccessful in accomplishing its plans, it may have to delay or terminate existing and/or planned clinical trials and other related activity, which could have a material adverse impact on its business. The Companys plans to continue as a going concern include obtaining capital from the sale of its equity securities, fees from licensing one or more of its product candidates, additio","filed_date":"2019-11-12","accession":"0001213900-19-022937","full_text":"https://origin.rootz.global/static/filing/0001213900-19-022937.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"Iomab-B receives favorable regulatory approval, we may not be successful in securing adequate reimbursement or establishing successful commercial operations. Any or all of these factors could have a material adverse impact on our business and ability to continue operations. 20 **We may be unable to establish sales, marketing and commercial supply capabilities** We do not currently have, nor have we ever had, commercial","filed_date":"2019-08-09","accession":"0001213900-19-015171","full_text":"https://origin.rootz.global/static/filing/0001213900-19-015171.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"Iomab-B receives favorable regulatory approval, we may not be successful in securing adequate reimbursement or establishing successful commercial operations. Any or all of these factors could have a material adverse impact on our business and ability to continue operations. 18 **We may be unable to establish sales, marketing and commercial supply capabilities** We do not currently have, nor have we ever had, commercial","filed_date":"2019-05-10","accession":"0001213900-19-008291","full_text":"https://origin.rootz.global/static/filing/0001213900-19-008291.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":17,"context":"Iomab-B receives favorable regulatory approval, we may not be successful in securing adequate reimbursement or establishing successful commercial operations. Any or all of these factors could have a material adverse impact on our business and ability to continue operations. 14 **We may be unable to establish sales, marketing and commercial supply capabilities** We do not currently have, nor have we ever had, commercial","filed_date":"2019-03-15","accession":"0001213900-19-004269","full_text":"https://origin.rootz.global/static/filing/0001213900-19-004269.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":14,"context":"nium?** In the last 12 months alone, we have seen two multi-billion-dollar acquisitions of companies with radiopharmaceutical-based therapies. The first being Advanced Accelerator Applications, Inc., acquired by Novartis for $3.9 billion and the most recent being Endocyte, also acquired by Novartis, for $2.1 billion. These follow Algeta that was acquired by Bayer in 2013 for $2.9 billion. There are also a growing number of","filed_date":"2018-11-16","accession":"0001213900-18-016080","full_text":"https://origin.rootz.global/static/filing/0001213900-18-016080.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":11,"context":"didates, for any of the foregoing reasons, could adversely affect our efforts to obtain regulatory approval for and to commercialize our product candidates, increase our operating expenses and have a material adverse effect on our financial results. Clinical trials may also be delayed or terminated as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated by us, t","filed_date":"2018-11-09","accession":"0001213900-18-015315","full_text":"https://origin.rootz.global/static/filing/0001213900-18-015315.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":17,"context":"Company with the SEC pursuant to Rule 424(b)(5) under the Securities Act and in accordance with Section 5(a) hereof, together with all documents and information incorporated therein by reference. (gg)Material Adverse Effect means any material adverse effect on (i) the enforceability of any Transaction Document, (ii) the results of operations, assets, business or financial condition of the Company and its Subsidiaries, t","filed_date":"2018-10-18","accession":"0001213900-18-014103","full_text":"https://origin.rootz.global/static/filing/0001213900-18-014103.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":11,"context":"didates, for any of the foregoing reasons, could adversely affect our efforts to obtain regulatory approval for and to commercialize our product candidates, increase our operating expenses and have a material adverse effect on our financial results. Clinical trials may also be delayed or terminated as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated by us, t","filed_date":"2018-08-09","accession":"0001213900-18-010603","full_text":"https://origin.rootz.global/static/filing/0001213900-18-010603.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":12,"context":"didates, for any of the foregoing reasons, could adversely affect our efforts to obtain regulatory approval for and to commercialize our product candidates, increase our operating expenses and have a material adverse effect on our financial results. Clinical trials may also be delayed or terminated as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated by us, t","filed_date":"2018-03-16","accession":"0001213900-18-003091","full_text":"https://origin.rootz.global/static/filing/0001213900-18-003091.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ATNM","company":"Actinium Pharmaceuticals, Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":13,"context":"votes cast in person or by proxy at the annual meeting and entitled to vote on the election of directors. Plurality means that the nominees receiving the greatest number of affirmative votes will be elected as directors, up to the number of directors to be chosen at the meeting. Broker non-votes will not affect the outcome of the election of directors because brokers do not have discretion to cast votes on this pro","filed_date":"2017-11-14","accession":"0001213900-17-012106","full_text":"https://origin.rootz.global/static/filing/0001213900-17-012106.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"96099fd11972109a3e527541491d641c08148b474471bb574b6aa02382c7b3e3","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"61d8cc7eee6a724d35ffa2320f56098658eb2df5689fcce6263a55099f2eceec","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":81,"hourly_limit":500,"remaining":419,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}